Astellas Pharma, Inc. (4503:TSX) Annual Reports & Investor Relations Material

Overview

Founded in 2005 through the merger of two Japanese pharmaceutical companies, Astellas has quickly established itself as a major player in the global pharmaceutical industry, with a focus on fields such as urology, immunology, and infectious diseases. The company is committed to investing in research and development to create new treatments for a range of medical conditions, and is also expanding its global presence through partnerships and acquisitions. Despite facing challenges such as patent expirations and regulatory scrutiny, Astellas is poised for continued growth in the years ahead as it continues to bring innovative treatments to patients in need.

Frequently Asked Questions

What is Astellas Pharma, Inc.'s ticker?

Astellas Pharma, Inc.'s ticker is 4503

What exchange is Astellas Pharma, Inc. traded on?

The company's shares trade on the TSX stock exchange

Where are Astellas Pharma, Inc.'s headquarters?

They are based in Tokyo, Japan

How many employees does Astellas Pharma, Inc. have?

There are 1001-5000 employees working at Astellas Pharma, Inc.

What is Astellas Pharma, Inc.'s website?

It is http://www.astellas.com/en/

What type of sector is Astellas Pharma, Inc.?

Astellas Pharma, Inc. is in the Healthcare sector

What type of industry is Astellas Pharma, Inc.?

Astellas Pharma, Inc. is in the Drug Manufacturers - Major industry

Who are Astellas Pharma, Inc.'s peers and competitors?

The following five companies are Astellas Pharma, Inc.'s industry peers:

- Hikma Pharmaceuticals

- GSK

- Aerie Pharmaceuticals Inc

- AstraZeneca

- Benchmark Holdings plc